Her-2在分化型甲状腺癌中的表达及意义

The Expression and Significance of Her-2 in Differentiated Thyroid Carcinoma

探讨Her-2在分化型甲状腺癌(DTC)中的表达意义。随机选取湖南省人民医院乳腺甲状腺外科近5年DTC64例,应用免疫组化法检测癌组织中的Her-2的表达,并以良性甲状腺疾病36例作为对照,分析Her-2对DTC的可能作用。结果Her-2在64例DTC中阳性表达为21.9%(14/64),而在36例甲状腺良性疾病中阳性表达为2.8%(1/36),两者间的表达存在差异显著性(P<0.05)。Her-2表达与临床分期和P53的表达均具有相关性(P均<0.05)。Her-2在DTC中呈较高表达,而在良性甲状腺疾病中表达率极低,Her-2可能与DTC的发生相关。

To investigate the expression and significance of Her--2 in differentiated thyroid carcinoma. Randomly chose 64 differentiated thyroid carcinoma （DTC） cases treated in the department of Breast Thyroid Surgery of Hunan Provincial People＇s Hospital in the past five years. Apply immunohistochemical method to detect the Her--2 expression in cancer tis- sues, take 36 cases of benign thyroid disease as controls, and analyze Her--2 DTC Possible role. The positive expression of Her--2 in 64 cases DTC was 21.90/00 （14/64}, while that in 36 cases of benign thyroid disease was 2.8% （1/36）. The expression between groups exists a significant difference （P〈0.05）. Her-2 expression with clinical stage and P53 expression were correlated （P〈0.05）. Her-2 showed higher expression in the DTC, but very low expression in benign thyroid disease, it may be related with the DTC occurrence.